The Federal Trade Commissioner has unanimously adopted a policy statement articulating its commitment to investigating rebates paid by drug manufacturers to pharmacy benefit managers in exchange for providing less favorable coverage to generics and biosimilars.
FTC Will Investigate Anti-Competitive Rebating But Any Enforcement Action Would Take Time
Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.
